Dendrite's Flagship Sales Force Effectiveness Solution Available on Microsoft SQL Server.

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of pharmaceutical industry solutions, today announced that it will make its flagship sales force effectiveness solution, Mobile Intelligence(TM), available on Microsoft SQL Server 2005 in the fourth quarter. This strategic decision was made to provide its customers with additional options that may result in a lower total cost of ownership.

Dendrite's Mobile Intelligence incorporates a revolutionary, human-centered design that mirrors the workflow of the representative. It enables users to be more efficient and effective in their detailing activity by providing access to all the information they require on a customer call with a few keystrokes. By developing Mobile intelligence using Microsoft .NET technologies, one of the world's most widely accepted development environments, Dendrite has ensured maximum flexibility for integration into its customers' existing infrastructure while reducing total cost of ownership.

"Dendrite's objective is to enable a wide range of pharmaceutical companies to capitalize on our solutions for competitive advantage," said Mark Theilken, Dendrite's president of Sales Solutions. "The global pharmaceutical industry is evolving rapidly and every company has unique circumstances that require a flexible, adaptable solution set. Our latest version of Mobile Intelligence ensures that a wider universe of pharmaceutical companies, regardless of size or geography, can benefit from this flexibility."

"SQL Server 2005 is a well-established and proven technology in the pharmaceutical market," said Steve Shihadeh, general manager, healthcare and life sciences, Microsoft. "Dendrite's innovative use of Microsoft technology provides seamless integration with desktop applications, enabling users to better connect and collaborate, ultimately allowing them to make more informed business decisions."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite and the Dendrite product names mentioned herein are the trademarks or registered trademarks of Dendrite International, Inc. The names of other companies or products mentioned herein may be the trademarks of their respective owners.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.